Compare MRLN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRLN | CNTB |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 140.4M |
| IPO Year | 2024 | 2020 |
| Metric | MRLN | CNTB |
|---|---|---|
| Price | $0.87 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $7.92 | $5.88 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $9.23 | $11,291.47 |
| Revenue Next Year | $153.29 | $74.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $0.73 |
| 52 Week High | $17.00 | $3.82 |
| Indicator | MRLN | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 21.28 | 39.50 |
| Support Level | N/A | N/A |
| Resistance Level | $3.45 | $2.84 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 7.46 | 48.21 |
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.